Breaking Finance News

Zacks Investment Research downgraded Medtronic PLC (NYSE:MDT) to Sell in a report released today.

Zacks Investment Research has downgraded Medtronic PLC (NYSE:MDT) to Sell in a report released on Tuesday November 29, 2016.

Previously on 11/24/2016, Needham reported on Medtronic PLC (NYSE:MDT) reduced the target price from $95.00 to $84.00. At the time, this indicated a possible upside of 0.11%.

Yesterday Medtronic PLC (NYSE:MDT) traded -0.77% lower at $73.53. The company’s 50-day moving average is $81.50 and its 200-day moving average is $84.68. The last closing price is down -13.29% from the 200-day moving average, compared to the S&P 500 which has decreased -0.03% over the same time period. 6,746,201 shares of the stock traded hands, up from an average trading volume of 5,296,660

See Chart Below

Medtronic PLC (NYSE:MDT)

Medtronic PLC has a 52 week low of $71.03 and a 52 week high of $89.27 with a P/E ratio of 24.45 The company’s market cap is currently $0.

In addition to Zacks Investment Research reporting its stock price target, a total of 22 brokers have issued a research note on the company. The average stock price target is $88.75 with 0 brokers rating the stock a strong buy, 0 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Information About Medtronic PLC (NYSE:MDT)

Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group segment includes Cardiac Rhythm & Heart Failure, Coronary & Structural Heart and Aortic & Peripheral Vascula. Its Minimally Invasive Technologies Group segment includes Surgical Solutions and Patient Monitoring and Recovery. Its Restorative Therapies Group segment includes Spine, Neuromodulation, Surgical Technologies and Neurovascular. Its Diabetes Group segment includes Intensive Insulin Management, Non-Intensive Diabetes Therapies and Diabetes Services & Solutions. The Company's subsidiaries include Medtronic, Inc. and HeartWare International, Inc.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.